These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28124380)

  • 21. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.
    Bai L; Wang F; Zhang DS; Li C; Jin Y; Wang DS; Chen DL; Qiu MZ; Luo HY; Wang ZQ; Li YH; Wang FH; Xu RH
    Sci Rep; 2015 Dec; 5():17717. PubMed ID: 26620439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas.
    Zhang X; Song YF; Lu HN; Wang DP; Zhang XS; Huang SL; Sun BL; Huang ZG
    World J Gastroenterol; 2015 Mar; 21(9):2629-37. PubMed ID: 25759530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
    Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
    BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
    Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
    Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
    Hansen TF; Carlsen AL; Heegaard NH; Sørensen FB; Jakobsen A
    Br J Cancer; 2015 Feb; 112(4):624-9. PubMed ID: 25584492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
    Yagisawa M; Sawada K; Nakamura Y; Fujii S; Yuki S; Komatsu Y; Yoshino T; Sakamoto N; Taniguchi H
    Clin Colorectal Cancer; 2021 Jun; 20(2):113-120.e1. PubMed ID: 33384243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
    Jary M; Vernerey D; Lecomte T; Dobi E; Ghiringhelli F; Monnien F; Godet Y; Kim S; Bouché O; Fratte S; Gonçalves A; Leger J; Queiroz L; Adotevi O; Bonnetain F; Borg C
    Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):603-12. PubMed ID: 25583947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.
    Bork U; Rahbari NN; Schölch S; Reissfelder C; Kahlert C; Büchler MW; Weitz J; Koch M
    Br J Cancer; 2015 Apr; 112(8):1306-13. PubMed ID: 25867263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
    BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia.
    Pedersen SK; Symonds EL; Baker RT; Murray DH; McEvoy A; Van Doorn SC; Mundt MW; Cole SR; Gopalsamy G; Mangira D; LaPointe LC; Dekker E; Young GP
    BMC Cancer; 2015 Oct; 15():654. PubMed ID: 26445409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
    Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
    Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.